Trial intelligence / Profile preview

Influenza and Pneumococcal Vaccination in COPD Patients

NCT07640841Phase 4Not yet recruiting

Sponsor
Jiangsu Provincial Center for Disease Control and Prevention
Start
Jun 2026
Primary completion
Jun 2027
01

Overview

A Phase 4 trial of trivalent influenza vaccine, 23-valent pneumococcal polysaccharide vaccine in influenza, pneumonia, sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Planned start Jun 2026; status: not yet recruiting.

02

Drugs

trivalent influenza vaccine23-valent pneumococcal polysaccharide vaccine
03

Conditions

influenzapneumonia

Beyond the preview

Go deeper on NCT07640841.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07640841.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call